Second line chemotherapy for metastatic colorectal carcinoma

Area of Science:

• Oncology
• Medical Oncology
• Clinical Pharmacology

Background:

• Metastatic colorectal carcinoma (mCRC) poses a significant treatment challenge, especially in patients refractory to standard chemotherapy.
• 5-fluorouracil and folinic acid are first-line agents for advanced colorectal cancer.
• Investigating novel combinations to overcome chemoresistance is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a combination regimen including mitomycin C, adriamycin, and lonidamine in patients with metastatic colorectal adenocarcinoma previously treated with 5-fluorouracil and folinic acid.
• To determine if lonidamine can potentiate the antineoplastic activity of standard chemotherapeutic agents in this patient population.

Main Methods:

• A cohort of 25 patients with metastatic colorectal carcinoma received mitomycin C, adriamycin, and lonidamine every 4 weeks.
• Patients had prior surgery and first-line chemotherapy with 5-fluorouracil and folinic acid.
• Objective response, duration of response, survival, and toxicity were assessed.

Main Results:

• Only one patient (4%) achieved a partial response, lasting over 5.8 months.
• Four patients (16%) experienced stable disease for a mean duration of 4.6 months.
• Median overall survival was 8.7 months, with significant toxicities including grade 3 thrombocytopenia (32%), leukopenia (20%), and vomiting (36%).

Conclusions:

• The combination of mitomycin C, adriamycin, and lonidamine demonstrated limited efficacy in metastatic colorectal adenocarcinoma resistant to 5-fluorouracil-based chemotherapy.
• Lonidamine did not appear to potentiate the activity of these chemotherapeutic drugs in human colorectal cancer.
• The findings suggest that lonidamine should be avoided in the treatment of colorectal cancer due to its minimal impact on response rate and survival.